Breaking News
Home / Australia / Gilead Strikes Out On Medivation – Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Strikes Out On Medivation – Gilead Sciences, Inc. (NASDAQ:GILD)

Medivation Inc. (NASDAQ:MDVN) Receives Consensus Rating of “Buy” from Analysts

Medivation Inc. (NASDAQ:MDVN) Receives Consensus Rating of “Buy” from Analysts

( Medivation Inc. (NASDAQ:MDVN) Receives Consensus Rating of “Buy” from Analysts )

– Medivation Inc. (NASDAQ:MDVN) has earned a consensus recommendation of “Buy” from the twenty-four brokerages that are covering the stock.One analyst has rated the stock with a sell recommendation, ten have given a hold recommendation, twelve have issued a buy recommendation and one has assigned a strong buy recommendation to the company.The average 12 month price target among brokers that have covered the stock in the last year is $73.10.
.

read more from here

Medivation Inc. (MDVN) to Post FY2016 Earnings of $0.97 Per Share, Jefferies Group Forecasts

Medivation Inc. (MDVN) to Post FY2016 Earnings of $0.97 Per Share, Jefferies Group Forecasts

( Medivation Inc. (MDVN) to Post FY2016 Earnings of $0.97 Per Share, Jefferies Group Forecasts )

– Medivation Inc. (NASDAQ:MDVN) – Research analysts at Jefferies Group issued their FY2016 earnings estimates for shares of Medivation in a note issued to investors on Wednesday.Jefferies Group analyst B. Amin forecasts that the firm will post earnings of $0.97 per share for the year.Jefferies Group has a “Hold” rating and a $60.00 price objective on the stock.
.

read more from here

Gilead Strikes Out On Medivation – Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Strikes Out On Medivation - Gilead Sciences, Inc. (NASDAQ:GILD)

( Gilead Strikes Out On Medivation – Gilead Sciences, Inc. (NASDAQ:GILD) )

– Gilead Sciences (NASDAQ:GILD) investors are likely feeling disappointed as multiple sources report that Pfizer (NYSE:PFE) is currently closing in on a $14 billion all-cash deal for Medivation (NASDAQ:MDVN), which has been the subject of M&A interest from other pharma companies such as Merck (NYSE:MRK), Sanofi (NYSE:SNY), Celgene (NASDAQ:CELG), and of course Gilead.Medivation’s prostate Cancer treatment Xtandi generates close to $2 billion in annual sales and is projected to earn $4.8 billion in annual sales by 2020.GILD data by YChartsMedivation would have been a great acquisition for Gilead as it would have provided a source of revenue growth and a blockbuster addition to the company’s currently sparse oncology department.
.

read more from here

About admin-Australia

Check Also

Stunning entries for 2018’s National Geographic Travel Photographer of the Year contest

as declared in Stunning entries for 2018’s National Geographic Travel Photographer of the Year contestThe …